GVAX immunotherapy for prostate cancer fails in Phase III
This article was originally published in Scrip
Executive Summary
Cell Genesys has terminated one of its two pivotal Phase III trials for GVAX immunotherapy for advanced prostate cancer, its lead developmental candidate, after the trial's independent data monitoring committee (IDMC) saw a higher number of deaths in the experimental arm compared with the control arm. Shares in the US biotech plunged by 72% on Nasdaq on August 27th.